TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player in the funding of healthcare and biotechnology in Europe.
Ascelia Pharma AB is an oncology-focused drug development company based in Malmö, Sweden, specializing in orphan drugs. Founded in 2000, the company is committed to addressing unmet medical needs through the development and commercialization of innovative therapies. Its lead product, Mangoral, is a novel non-gadolinium contrast agent currently in Phase III clinical trials for MRI scans of the liver. Additionally, Ascelia is advancing Oncoral, an oral chemotherapy tablet in Phase II trials aimed at treating gastric cancer. Through these initiatives, Ascelia Pharma seeks to provide effective treatment options for patients with specific oncology needs.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.
Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. The company focuses on developing innovative therapies for unmet needs in neuropsychiatric disorders, particularly anxiety, mood, and stress-related conditions. Synendos utilizes a novel drug target within the endocannabinoid system to restore the brain's natural functioning. Its therapies involve the modulation of cannabinoid activity and the inhibition of endocannabinoid transport across cell membranes, addressing altered neurotransmission in various brain regions. This approach presents a promising solution to the significant demand for effective pharmacological treatments, especially for conditions like post-traumatic stress disorder (PTSD), which currently lacks adequate therapeutic options.
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
Forendo Pharma is a drug discovery and development company based in Turku, Finland, established in 2013. The company specializes in creating novel therapies for urological and endocrinological diseases, focusing on tissue-specific regulation of sex hormone mechanisms. Its primary product, Fispemifene, is a selective estrogen receptor modulator designed to address the symptoms of low testosterone in men. Additionally, Forendo Pharma is developing a 17HSD1-inhibitor targeting endometriosis, which aims to meet unmet medical needs in both women's and men's health. Through its innovative approach, Forendo Pharma seeks to enhance treatment options for a range of gynecological and urological conditions.
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
Prexton Therapeutics is a Swiss-based biopharmaceutical company, founded in 2012 by Francois Conquet and MS Ventures as part of the Merck Serono Entrepreneur Partnership Program, a facility to support the creation of spin-offs from Merck Serono. Prexton Therapeutics applies a new scientific approach that fully integrates molecular, behavioural and chemistry technologies to address Parkinson’s disease and other brain disorders. Prexton Therapeutics uses its powerful discovery platform to target specific novel compounds focused on the treatment of Parkinson’s disease.
Dubsmash, Inc. develops and operates a web-based hosting, communications, and content creation platform and mobile application. The company offers a micro-video-entertainment application, which allows content creators to create and share dubbed sound recordings, videos, information, text, graphics, or related content. The company was founded in 2017 and is based in New York, New York.
OxThera AB manufactures products for the treatment of primary and secondary hyperoxaluria with bacteria and enzymes. It offers Oxabact, an orally delivered composition of live bacteria to promote the removal of endogenously produced oxalate for the treatment of primary hyperoxaluria and Oxazyme, a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase for the treatment of dietary hyperoxaluria and prevention of kidney stones. The company was founded in 2005 and is based in Stockholm, Sweden with an additional location in Knoxville, Tennessee.
Rigontec GmbH is a biopharmaceutical company that develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The company develops ImOl100, a compound stimulating the immune receptor retinoic acid-inducible gene I, which recognizes viral RNA. Its ImOl100 is also a minimal mimic of naturally occurring 3pRNA, a motif typically occurring in viral RNAs. The company’s compounds avoid the pitfalls of cancer vaccines, checkpoint inhibitors, and therapeutics based on the identification of tumor antigens. Rigontec GmbH was founded in 2014 and is based in Planegg, Germany. As of October 26, 2017, Rigontec GmbH operates as a subsidiary of Merck & Co., Inc.
F2G Ltd develops novel therapies to treat fungal diseases. It primarily focuses on developing an F3 series of anti-mold compound, which is an antifungal agent. The company offers orotomides that are antifungal agents against Aspergillus and other filamentous molds. F2G Ltd was formerly known as Functional Fungal Genomics Ltd and changed its name to F2G Ltd in July 1999. F2G Ltd was founded in 1998 and is based in Manchester, United Kingdom.
Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies.
Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.
Corti is an artificial intelligence platform designed to assist emergency medical dispatchers in making critical, life-saving decisions. By enhancing the medical triaging process, Corti reduces errors and improves the accuracy of human decision-making, ultimately aiming to save more lives in emergency situations. The company's technology serves as an intelligent partner, providing valuable insights and support to dispatchers as they navigate high-pressure scenarios.
Dubsmash, Inc. develops and operates a web-based hosting, communications, and content creation platform and mobile application. The company offers a micro-video-entertainment application, which allows content creators to create and share dubbed sound recordings, videos, information, text, graphics, or related content. The company was founded in 2017 and is based in New York, New York.
Rigontec GmbH is a biopharmaceutical company that develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The company develops ImOl100, a compound stimulating the immune receptor retinoic acid-inducible gene I, which recognizes viral RNA. Its ImOl100 is also a minimal mimic of naturally occurring 3pRNA, a motif typically occurring in viral RNAs. The company’s compounds avoid the pitfalls of cancer vaccines, checkpoint inhibitors, and therapeutics based on the identification of tumor antigens. Rigontec GmbH was founded in 2014 and is based in Planegg, Germany. As of October 26, 2017, Rigontec GmbH operates as a subsidiary of Merck & Co., Inc.
Prexton Therapeutics is a Swiss-based biopharmaceutical company, founded in 2012 by Francois Conquet and MS Ventures as part of the Merck Serono Entrepreneur Partnership Program, a facility to support the creation of spin-offs from Merck Serono. Prexton Therapeutics applies a new scientific approach that fully integrates molecular, behavioural and chemistry technologies to address Parkinson’s disease and other brain disorders. Prexton Therapeutics uses its powerful discovery platform to target specific novel compounds focused on the treatment of Parkinson’s disease.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies.
Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.
Pulmologix AB develops, manufactures, and sells oral non-steroidal anti-asthmatic drug for the treatment of early onset allergic asthma. The company was founded in 2006 and is based in Stockholm, Sweden.
In 2013, the company's first spinal fusion implant in the Statur product line received CE mark. At the same time, the company was ISO 13485 certified demonstrating its adherence to the highest quality standards. With these accomplishments, the company is now ready to be introduced on the European and Canadian markets.
In early 2005, FBC Device was founded. With initial financial support in place, FBC Device was established and initial patents filed in late 2005. In December 2010, the European patent was granted and further funding raised, and in 2011 the US patent was granted.
JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.
Egalet is a specialty pharmaceutical company that develops pain management products. The company is developing a pipeline of abuse-resistant opioids that are nearing pivotal testing. Egalet has pioneered one of the world’s first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet and has optimized the abuse deterrent properties that can be applied to a broad range of opioids and non-opioids.
Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies.
Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.
Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.
JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.
The company is based on the original discovery that leukemic stem cells in patients with chronic myeloid leukemia (CML) express a cell-surface receptor, whereas corresponding normal hematopoietic stem cells do not express this receptor. Stem cells from patients with acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) has also been shown to have and upregulation of the receptor. Cantargia uses this receptor, the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia
Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.
F2G Ltd develops novel therapies to treat fungal diseases. It primarily focuses on developing an F3 series of anti-mold compound, which is an antifungal agent. The company offers orotomides that are antifungal agents against Aspergillus and other filamentous molds. F2G Ltd was formerly known as Functional Fungal Genomics Ltd and changed its name to F2G Ltd in July 1999. F2G Ltd was founded in 1998 and is based in Manchester, United Kingdom.
Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.
Nuevolution AB is a biopharmaceutical company based in Copenhagen, Denmark, founded in 2001. It specializes in developing drug treatments for oncology and chronic inflammatory diseases, leveraging its unique Chemetics platform for drug discovery. This platform combines proven wet chemistry and molecular biology, allowing for the synthesis and screening of over one billion small molecule compounds and synthetic biologics. Nuevolution is focused on several therapeutic programs, including ROR?t inhibitors and IL-17A inhibitors for chronic inflammatory diseases, as well as GRP78 for oncology. The company has established collaborations with notable pharmaceutical partners, including Amgen and Janssen Biotech, and is involved in joint ventures aimed at discovering novel small molecule drugs targeting epigenetic factors. Through its innovative technology, Nuevolution aims to address significant unmet medical needs in various therapeutic areas.
Adenium Biotech ApS is a Danish biopharmaceutical company founded in 2011, focused on developing and commercializing innovative antibiotics to address multi-drug resistant bacterial infections. The company specializes in solutions for hospital-acquired infections, particularly complicated urinary tract infections and pneumonia caused by resistant gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Its lead product, Arenicin, is a non-toxic antimicrobial peptide derived from lugworms, demonstrating strong efficacy against gram-negative pathogens. Adenium Biotech employs a semi-virtual model, leveraging a small team of experts and an international scientific advisory board to advance the Arenicin program through clinical development towards regulatory approval. The company's goal is to provide effective treatments for infections that are increasingly difficult to manage due to antibiotic resistance.
Egalet is a specialty pharmaceutical company that develops pain management products. The company is developing a pipeline of abuse-resistant opioids that are nearing pivotal testing. Egalet has pioneered one of the world’s first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet and has optimized the abuse deterrent properties that can be applied to a broad range of opioids and non-opioids.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies.
Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
Vaximm specializes in developing active immunotherapies, specifically oral T-cell vaccines, for cancer patients. The company's lead product candidate, VXM01, aims to target the tumor vasculature, a critical component for tumor growth beyond microscopic size. Vaximm's innovative approach utilizes modified attenuated bacteria as first-in-class oral T-cell activators, allowing for flexible targeting of various cancer-related antigens. Preclinical studies have demonstrated significant anti-tumor activity, and Vaximm is poised to advance into human clinical trials, marking a significant step in offering advanced treatment options for cancer patients.
Acarix AB is a medical technology company that specializes in developing and commercializing diagnostic tests for cardiovascular diseases, focusing on non-invasive and non-radiation methods. The primary product, the CADScor System, is designed to diagnose coronary artery disease by utilizing a sensor that records, processes, and displays heart signals. Founded in 2009 and headquartered in Malmö, Sweden, Acarix operates in Germany, Sweden, Denmark, and other international markets. The company's technology is rooted in pioneering research from Aalborg University in Denmark, which began in 2004. Acarix emerged as a spin-out from Coloplast A/S, with significant backing from both Coloplast and Aalborg University as major shareholders. The company has successfully attracted venture capital and public funding to support its research and development efforts, positioning itself as a leader in the field of cardiovascular diagnostics.
Action Pharma A/S develops novel drugs for cardio vascular treatment. The company also conducts pre-clinical and early clinical trials of new pharmaceutical products and treatment concepts for cardiovascular, inflammatory, and acquired metabolic diseases. Its products include COMPOUND AP1189, an oral anti-inflammatory compound under development for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and COMPOUND AP405, a modified MSH peptide analogue under development for the treatment of inflammatory skin diseases, such as atopic dermatitis. Action Pharma A/S was founded in 2000 and is based in Aarhus, Denmark.
JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.
Biomonitor, founded in 2003 by Professor Klaus Bendtzen and Arsalan Kharazmi as a spinout from the University of Copenhagen, specializes in pharmaceutical development services. The company leverages Professor Bendtzen's extensive research experience in inflammation and immunology, particularly his discoveries related to patient responses to biopharmaceuticals. It has been established that some patients develop antibodies against the proteins and peptides used in these treatments, which can hinder their efficacy. Consequently, Biomonitor focuses on creating methods to monitor these biopharmaceuticals, ensuring that patients receive optimal therapeutic benefits. Since its inception, the company has experienced significant growth, reflecting its commitment to improving patient care in chronic disease management.
Action Pharma A/S develops novel drugs for cardio vascular treatment. The company also conducts pre-clinical and early clinical trials of new pharmaceutical products and treatment concepts for cardiovascular, inflammatory, and acquired metabolic diseases. Its products include COMPOUND AP1189, an oral anti-inflammatory compound under development for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and COMPOUND AP405, a modified MSH peptide analogue under development for the treatment of inflammatory skin diseases, such as atopic dermatitis. Action Pharma A/S was founded in 2000 and is based in Aarhus, Denmark.
Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.